Hatice Canan Hasanoğlu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hatice Canan Hasanoğlu has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Hatice Kilic
Ankara Yıldırım Beyazıt University, School of Medicine, Department of Pulmonary Diseases. Ankara, Türkiye
8 shared publications - Aysegul Karalezli
Faculty of Medicine, Ankara Yildirim Beyazit University, 06800 Ankara, Turkey
7 shared publications - Habibe Hezer
Department of Chest Diseases, Ankara Bilkent City Hospital, 06800 Ankara, Türkiye
7 shared publications - Emine Argüder
Faculty of Medicine Department of Chest Diseases Ankara Yıldırım Beyazıt University Ankara Türkiye
6 shared publications - Ebru Şengül Parlak
Department of Chest Diseases Ankara Bilkent City Hospital Ankara Türkiye
5 shared publications - Elif Babaoglu
Hacettepe Univ, Dept Pulm Dis, Fac Med, Ankara, Turkey
3 shared publications
Latest Publications
- 21 May 2026
- Published by MediHealth Academy in Journal of Pulmonology and Intensive Care
- Vol. 4 (2) , 7-12
Ischemia-modified albumin as a marker of disease severity and hospitalization in community-acquired pneumonia: a prospective case–control study
Aims: Community-acquired pneumonia (CAP) is an important public health problem because of its high morbidity, mortality, and health care costs. Many biomarkers have been used to determine the severity and prognosis of pneumonia. Ischemia-modified albumin (IMA) is a marker of the recently used oxidant-antioxidant mechanism and has been found to increase in many inflammatory conditions. Objectives: To investigate the role of the levels of IMA in CAP and to evaluate its relationship with pneumonia severity. Methods: A total of 150 patients with a diagnosis of CAP and 150 healthy individuals were included in the study. IMA levels were evaluated in both groups. The patients with CAP were divided into ambulatory, ward and intensive care groups, and their IMA levels were compared. Results: There was no significant difference between the two groups in terms of age or gender (p>0.05 for both). No significant difference was observed in the IMA levels of the patient and control groups (p>0.05). The lowest IMA level was observed in the ambulatory group (p=0.001). When the patients in the ambulatory and hospitalized (ward and intensive care together) groups were evaluated, the cut-off value of IMA was 77.60 ABSU, sensitivity was 64.9%, specificity was 75.0%, positive predictive value was 89.2%, and negative predictive value was 40.3%. Conclusion: In the management of patients with CAP, IMA seems to be a useful marker for CAP severity and hospitalization decision.
- 21 May 2026
- Published by MediHealth Academy in Journal of Pulmonology and Intensive Care
- Vol. 4 (2) , 7-12
Ischemia-modified albumin as a marker of disease severity and hospitalization in community-acquired pneumonia: a prospective case–control study
Aims: Community-acquired pneumonia (CAP) is an important public health problem because of its high morbidity, mortality, and health care costs. Many biomarkers have been used to determine the severity and prognosis of pneumonia. Ischemia-modified albumin (IMA) is a marker of the recently used oxidant-antioxidant mechanism and has been found to increase in many inflammatory conditions. Objectives: To investigate the role of the levels of IMA in CAP and to evaluate its relationship with pneumonia severity. Methods: A total of 150 patients with a diagnosis of CAP and 150 healthy individuals were included in the study. IMA levels were evaluated in both groups. The patients with CAP were divided into ambulatory, ward and intensive care groups, and their IMA levels were compared. Results: There was no significant difference between the two groups in terms of age or gender (p>0.05 for both). No significant difference was observed in the IMA levels of the patient and control groups (p>0.05). The lowest IMA level was observed in the ambulatory group (p=0.001). When the patients in the ambulatory and hospitalized (ward and intensive care together) groups were evaluated, the cut-off value of IMA was 77.60 ABSU, sensitivity was 64.9%, specificity was 75.0%, positive predictive value was 89.2%, and negative predictive value was 40.3%. Conclusion: In the management of patients with CAP, IMA seems to be a useful marker for CAP severity and hospitalization decision.
- Open Access
- 10 September 2024
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 72 (3) , 219-228
Is using inhaled corticosteroid effective against COVID-19 pneumonia severity and mortality?
It is known that the use of inhaled corticosteroids increases the incidence of pneumonia in patients followed up with the diagnosis of chronic asthma and chronic obstructive pulmonary disease (COPD). This study aimed to investigate the contribution of inhaled steroid use to pneumonia severity and mortality in cases with COVID-19 pneumonia. The study is a retrospective, observational study. Among the cases admitted to the pandemic clinic, patients diagnosed with COVID-19 pneumonia were included. The plan was to compare cases who received and did not receive inhaled corticosteroids in terms of pneumonia severity and mortality. In order to define risk factors for mortality, univariate and multivariable negative binomial regression analyses were performed. In our study, it was observed that n= 540 (75%) cases did not receive inhaled corticosteroids (group 1), and 180 (25%) cases used inhaled corti costeroids (group 2). Group 1 and group 2 cases were compared in terms of pneumonia severity with no significant difference between the two groups (p= 0.11). Then, risk factors affecting mortality in all cases were examined with univariate analyses. Increasing age, applying mechanical ventilation, having severe pneumonia, having interstitial lung disease, and applying prone position were found to be statistically significant factors in mortality (p < 0.05). In conclusion, in our study, it was observed that the use of inhaled corticosteroids did not increase the severity of pneumonia and mortality. It was thought that the treatment they received could be continued when the patients treated with inhaled corticosteroids due to asthma and COPD had COVID-19 pneumonia.
- 10 September 2024
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 72 (3) , 219-228
Open AccessIs using inhaled corticosteroid effective against COVID-19 pneumonia severity and mortality?
It is known that the use of inhaled corticosteroids increases the incidence of pneumonia in patients followed up with the diagnosis of chronic asthma and chronic obstructive pulmonary disease (COPD). This study aimed to investigate the contribution of inhaled steroid use to pneumonia severity and mortality in cases with COVID-19 pneumonia. The study is a retrospective, observational study. Among the cases admitted to the pandemic clinic, patients diagnosed with COVID-19 pneumonia were included. The plan was to compare cases who received and did not receive inhaled corticosteroids in terms of pneumonia severity and mortality. In order to define risk factors for mortality, univariate and multivariable negative binomial regression analyses were performed. In our study, it was observed that n= 540 (75%) cases did not receive inhaled corticosteroids (group 1), and 180 (25%) cases used inhaled corti costeroids (group 2). Group 1 and group 2 cases were compared in terms of pneumonia severity with no significant difference between the two groups (p= 0.11). Then, risk factors affecting mortality in all cases were examined with univariate analyses. Increasing age, applying mechanical ventilation, having severe pneumonia, having interstitial lung disease, and applying prone position were found to be statistically significant factors in mortality (p < 0.05). In conclusion, in our study, it was observed that the use of inhaled corticosteroids did not increase the severity of pneumonia and mortality. It was thought that the treatment they received could be continued when the patients treated with inhaled corticosteroids due to asthma and COPD had COVID-19 pneumonia.
- Open Access
- 30 June 2023
- Published by Kocaeli University in Acta Medica Nicomedia
- Vol. 6 (2) , 179-183
Evaluation of Upper Extremity Venous Thrombosis with Doppler Ultrasonography in Peripheral Venous Line Applied Patients
Objectives: Peripherally inserted venous lines (PVL) may increase the risk of venous thrombosis due to vessel wall disarrangement. Aim of this study is to identify the cases of upper extremity venous thrombosis (UEVT) related to PVL since most of the PVLs applied to upper extremities. Methods: Sixty-nine hospitalized patients with previous or present PVL insertions were included in this prospective study. Upper extremity Doppler compression ultrasonography (USG) examination were performed to on all patients. The cases with detected UEVTs were evaluated as group 1 and the remaining cases were evaluated as group 2. Demographic parameters, PVL applications, intravenous treatments were compared between the groups. Results: UEVT was diagnosed by Doppler USG in 26 (37.7%) patients out of 69 patients. Lower extremity thrombosis was found in 10 (14.49%) patients. UEVT was observed in cephalic vein in 14 (53.8%) and in basilic vein in four (15.4%) out of 26 (37.7%) patients. Axillary and brachial deep UEVT was located in two (2.9%) cases. Superficial UEVT was found in 24 (34.8%) cases. Ceftriaxone, cefoperazone/sulbactam and esomeprazole were the mostly associated treatments with UEVT. UEVT was detected in five patients with PVL that were inserted only for drawing blood. Conclusion: PVL is a risk factor for UEVT since almost 1/3 of the patients revealed UEVT. When PVL is no longer needed or the need for intravenous therapy decreases, oral therapy should be planned and PVL should be removed. Removal of PVL appears to be necessary to avoid UEVT.
- 30 June 2023
- Published by Kocaeli University in Acta Medica Nicomedia
- Vol. 6 (2) , 179-183
Open AccessEvaluation of Upper Extremity Venous Thrombosis with Doppler Ultrasonography in Peripheral Venous Line Applied Patients
Objectives: Peripherally inserted venous lines (PVL) may increase the risk of venous thrombosis due to vessel wall disarrangement. Aim of this study is to identify the cases of upper extremity venous thrombosis (UEVT) related to PVL since most of the PVLs applied to upper extremities. Methods: Sixty-nine hospitalized patients with previous or present PVL insertions were included in this prospective study. Upper extremity Doppler compression ultrasonography (USG) examination were performed to on all patients. The cases with detected UEVTs were evaluated as group 1 and the remaining cases were evaluated as group 2. Demographic parameters, PVL applications, intravenous treatments were compared between the groups. Results: UEVT was diagnosed by Doppler USG in 26 (37.7%) patients out of 69 patients. Lower extremity thrombosis was found in 10 (14.49%) patients. UEVT was observed in cephalic vein in 14 (53.8%) and in basilic vein in four (15.4%) out of 26 (37.7%) patients. Axillary and brachial deep UEVT was located in two (2.9%) cases. Superficial UEVT was found in 24 (34.8%) cases. Ceftriaxone, cefoperazone/sulbactam and esomeprazole were the mostly associated treatments with UEVT. UEVT was detected in five patients with PVL that were inserted only for drawing blood. Conclusion: PVL is a risk factor for UEVT since almost 1/3 of the patients revealed UEVT. When PVL is no longer needed or the need for intravenous therapy decreases, oral therapy should be planned and PVL should be removed. Removal of PVL appears to be necessary to avoid UEVT.
- 26 September 2022
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 70 (3) , 279-286
Comparison of clinical and radiological characteristics of COVID-19 patients with and without pneumothorax and/or pneumediastinum
Pneumothorax (PTX) and pneumomediastinum (PM) are frequently encountered in patients with Coronavirus disease 2019 (COVID-19) and complicate the management of these patients. In this study, we aimed to evaluate the risk factors that cause PTX/PM complications in patients hospitalized due to COVID-19 pneumonia and the effects of these complications on the course of the disease. A total of 503 patients with COVID-19 hospitalized in the COVID-19 ward or intensive care unit (ICU) between September 2020 and December 2020 were included in the study. The median age of patients was 65 (min-max, 21-99) years. Of the patients 299 (59.4%) were male and 204 (40.6%) were female. Of the cases, 26 (5.2%) developed PTX or PM. The patients who developed PTX/PM were older than patients who did not [58.5 (min-max, 21-96) vs 65 years (min-max, 22-99), p= 0.029]. The percentage of PTX/PM development was significantly higher in male patients [F/M= 4/22 (2/7.4%) vs 200/277 (98/92.6%), p= 0.007]. Hypertension as a comorbidity was more commonly seen in the group without PTX/PM (p= 0.007). Ground-glass opacity was the most common tomographic finding in both groups, it was significantly higher in those who did not develop PTX/PM (p<0.001). The length of hospital stay was shorter in patients with PTX/PM (p<0.001), but mortality was higher (p= 0.04). PTX/PM were relatively more common in COVID-19 patients. These complications may negatively affect the prognosis of the disease.
- 26 September 2022
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 70 (3) , 279-286
Comparison of clinical and radiological characteristics of COVID-19 patients with and without pneumothorax and/or pneumediastinum
Pneumothorax (PTX) and pneumomediastinum (PM) are frequently encountered in patients with Coronavirus disease 2019 (COVID-19) and complicate the management of these patients. In this study, we aimed to evaluate the risk factors that cause PTX/PM complications in patients hospitalized due to COVID-19 pneumonia and the effects of these complications on the course of the disease. A total of 503 patients with COVID-19 hospitalized in the COVID-19 ward or intensive care unit (ICU) between September 2020 and December 2020 were included in the study. The median age of patients was 65 (min-max, 21-99) years. Of the patients 299 (59.4%) were male and 204 (40.6%) were female. Of the cases, 26 (5.2%) developed PTX or PM. The patients who developed PTX/PM were older than patients who did not [58.5 (min-max, 21-96) vs 65 years (min-max, 22-99), p= 0.029]. The percentage of PTX/PM development was significantly higher in male patients [F/M= 4/22 (2/7.4%) vs 200/277 (98/92.6%), p= 0.007]. Hypertension as a comorbidity was more commonly seen in the group without PTX/PM (p= 0.007). Ground-glass opacity was the most common tomographic finding in both groups, it was significantly higher in those who did not develop PTX/PM (p<0.001). The length of hospital stay was shorter in patients with PTX/PM (p<0.001), but mortality was higher (p= 0.04). PTX/PM were relatively more common in COVID-19 patients. These complications may negatively affect the prognosis of the disease.
- 14 July 2021
- Published by Galenos Yayinevi in Turkish Thoracic Journal
- Vol. 22 (4) , 339-345
The Role of Pneumococcal Pneumonia among Community-Acquired Pneumonia in Adult Turkish Population: TurkCAP Study
Streptococcus pneumoniae,community-acquired pneumonia,adult
- 14 July 2021
- Published by Galenos Yayinevi in Turkish Thoracic Journal
- Vol. 22 (4) , 339-345
The Role of Pneumococcal Pneumonia among Community-Acquired Pneumonia in Adult Turkish Population: TurkCAP Study
Streptococcus pneumoniae,community-acquired pneumonia,adult
- 15 September 2020
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 68 (3) , 337-341
Behcet’s disease presenting with pulmonary thromboembolism
- 15 September 2020
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 68 (3) , 337-341
Behcet’s disease presenting with pulmonary thromboembolism
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64) , 1863
Comparision of side effects between thrombolytic and anticoagulation therapy in patients with Pulmonary Embolism
Purpose: The treatment of Pulmonary Embolism (PE) which is life threatening disease must be planned considering risk – benefit relationship. In this study, patients with PE given thrombolytic therapy, low-molecular-weight heparin and warfarin were monitored for 5 years to compare them in terms of hemorrhage side effect due to therapy. Method: A total of 219 patients were included in the study. 50.2% (n=109) of the patient’s were female and 49.8% (n=110) were male, (p=0.20). Clinical findings, radiologic and laboratory parameters were recorded retrospectively. A total of 121 (55.25%) patients were given thrombolytic therapy (Group 1 n=121). Enoxaparin therapy was given to 205 patients (Group 2). During therapy maintenance, warfarin therapy conducted for 159 patients (Group 3). Results: Cerebral hemorrhage observed in 1 case (0.83%) in group 1, 2 case (0.98%) in group 2 and 1 case (0.62%) in group 3 (p>0.05). Gastrointestinal system (GI) bleeding happened 2 cases (1.65%) in group 1 and 2 cases (0.98%) in group 2 (p>0.05). Minor bleeding was observed at similar rates due to the treatments. There was no fatality due to hemorrhage. There is no significant difference in terms of death, recurrence, residuel chronic thrombus and chronic PE in the follow up for five years between rt-PA group (group1) and non rt-PA group (p>0.05). Conclusion: According to our results; major hemorrhage observed similar in thrombolytic, enoxaparin and warfarin therapy. Study results about the rate of cerebral hemorrhage related to thrombolytic therapy was low in contrast to the results reported in some literature before.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64) , 1863
Comparision of side effects between thrombolytic and anticoagulation therapy in patients with Pulmonary Embolism
Purpose: The treatment of Pulmonary Embolism (PE) which is life threatening disease must be planned considering risk – benefit relationship. In this study, patients with PE given thrombolytic therapy, low-molecular-weight heparin and warfarin were monitored for 5 years to compare them in terms of hemorrhage side effect due to therapy. Method: A total of 219 patients were included in the study. 50.2% (n=109) of the patient’s were female and 49.8% (n=110) were male, (p=0.20). Clinical findings, radiologic and laboratory parameters were recorded retrospectively. A total of 121 (55.25%) patients were given thrombolytic therapy (Group 1 n=121). Enoxaparin therapy was given to 205 patients (Group 2). During therapy maintenance, warfarin therapy conducted for 159 patients (Group 3). Results: Cerebral hemorrhage observed in 1 case (0.83%) in group 1, 2 case (0.98%) in group 2 and 1 case (0.62%) in group 3 (p>0.05). Gastrointestinal system (GI) bleeding happened 2 cases (1.65%) in group 1 and 2 cases (0.98%) in group 2 (p>0.05). Minor bleeding was observed at similar rates due to the treatments. There was no fatality due to hemorrhage. There is no significant difference in terms of death, recurrence, residuel chronic thrombus and chronic PE in the follow up for five years between rt-PA group (group1) and non rt-PA group (p>0.05). Conclusion: According to our results; major hemorrhage observed similar in thrombolytic, enoxaparin and warfarin therapy. Study results about the rate of cerebral hemorrhage related to thrombolytic therapy was low in contrast to the results reported in some literature before.
- 1 May 2020
- Published by AVES YAYINCILIK A.Ş. in Balkan Medical Journal
- Vol. 37 (3) , 157-162
The Geographical Distribution of Morbidity Caused By Chronic Obstructive Pulmonary Disease in Turkey: COPDTURKEY-2
Background: Chronic obstructive pulmonary disease (COPD) is one of the most prevalent causes for morbidity and mortality, and it creates a cumulative economic and social burden. Aims: To determine the distribution of the prevalence of patients in Turkey who were diagnosed with COPD and their morbidity rates, according to the regions and cities they belong to. Moreover, the study contributes to the prevention and cure services of COPD that should be planned in the future. Study Design: A retrospective cohort. Methods: The database of the Social Security Institution from 2016 has been scanned. All the data with prescription registration, with the code ICD-10, J44.0-J44.9, which were aimed for diagnosing and/or cure, have been evaluated with a retrospective cohort. Results: In 2016, 955,369 patients who were admitted as outpatients to the hospitals were diagnosed with COPD. The average number of annual COPD cases that were admitted was 2.09. Twenty percent (20%) of the outpatient applications were via emergency room. The rate of hospitalization among the applicants was 17.75%. with a total of 1,994,325. The average annual number of hospitalizations of men was higher than that of women. The average number of hospitalization days was 6.52. The region with the highest prevalence of outpatient admission and hospitalization was the Black Sea Region. Conclusion: The high rate of hospitalization was considered to be the outcome of the insufficient "outpatient" management.
- 1 May 2020
- Published by AVES YAYINCILIK A.Ş. in Balkan Medical Journal
- Vol. 37 (3) , 157-162
The Geographical Distribution of Morbidity Caused By Chronic Obstructive Pulmonary Disease in Turkey: COPDTURKEY-2
Background: Chronic obstructive pulmonary disease (COPD) is one of the most prevalent causes for morbidity and mortality, and it creates a cumulative economic and social burden. Aims: To determine the distribution of the prevalence of patients in Turkey who were diagnosed with COPD and their morbidity rates, according to the regions and cities they belong to. Moreover, the study contributes to the prevention and cure services of COPD that should be planned in the future. Study Design: A retrospective cohort. Methods: The database of the Social Security Institution from 2016 has been scanned. All the data with prescription registration, with the code ICD-10, J44.0-J44.9, which were aimed for diagnosing and/or cure, have been evaluated with a retrospective cohort. Results: In 2016, 955,369 patients who were admitted as outpatients to the hospitals were diagnosed with COPD. The average number of annual COPD cases that were admitted was 2.09. Twenty percent (20%) of the outpatient applications were via emergency room. The rate of hospitalization among the applicants was 17.75%. with a total of 1,994,325. The average annual number of hospitalizations of men was higher than that of women. The average number of hospitalization days was 6.52. The region with the highest prevalence of outpatient admission and hospitalization was the Black Sea Region. Conclusion: The high rate of hospitalization was considered to be the outcome of the insufficient "outpatient" management.
- 6 March 2020
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 14 (7) , 652-658
Thiol‐disulfide as a novel indicator of obstructive sleep apnea
Introduction: Obstructive sleep apnea (OSA) is an oxidative stress disease, which has been considered to be a notable risk and associated with increased cardiovascular morbidity and mortality. Thiol‐disulfide homeostasis is as a novel indicator of oxidative stress.Objectives: We aimed to evaluate thiol‐disulfide homeostasis in a large patient population with OSA.Methods: A total of 230 with OSA and 40 healthy controls were included in the study. Inclusion criteria for OSA patients are having apnoea‐hypopnoea index of ≥5/hour, being more than 18 years of age and having no previous treatment for OSA. Thiol‐disulfide analysis was done for the patients and control group. Blood thiol‐disulfide homeostasis was analysed using the new automatic method, developed by Erel and Neşelioğlu.Results: Among all OSA subjects, 149 (64.8%) were males and the mean ages of the patients were 53.38 ± 10.22. Total thiol, native thiol (SH) and disulfide (SS) levels were significantly lower in OSA group compared to the control group (P < .001, P < .001 and P = .039 respectively). Also, total thiol and native thiol (SH) were significantly different between the groups according to OSA severity (mild‐moderate to severe OSA) (P < .001 and P < .001 respectively). Thiol‐disulfide redox parameters were correlated with apnoea‐hypopnoea index (AHI) scores.Conclusion: The present prospective study showed that thiol/disulfide homeostasis was unbalanced in OSA patients. Especially, in OSA patients have low level of thiol/disulfide redox parameters when compared to healthy subjects. Evaluating thiol‐disulfide homeostasis in OSA may be a contributing aspect to assessment and monitoring of the patient.
- 6 March 2020
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 14 (7) , 652-658
Thiol‐disulfide as a novel indicator of obstructive sleep apnea
Introduction: Obstructive sleep apnea (OSA) is an oxidative stress disease, which has been considered to be a notable risk and associated with increased cardiovascular morbidity and mortality. Thiol‐disulfide homeostasis is as a novel indicator of oxidative stress.Objectives: We aimed to evaluate thiol‐disulfide homeostasis in a large patient population with OSA.Methods: A total of 230 with OSA and 40 healthy controls were included in the study. Inclusion criteria for OSA patients are having apnoea‐hypopnoea index of ≥5/hour, being more than 18 years of age and having no previous treatment for OSA. Thiol‐disulfide analysis was done for the patients and control group. Blood thiol‐disulfide homeostasis was analysed using the new automatic method, developed by Erel and Neşelioğlu.Results: Among all OSA subjects, 149 (64.8%) were males and the mean ages of the patients were 53.38 ± 10.22. Total thiol, native thiol (SH) and disulfide (SS) levels were significantly lower in OSA group compared to the control group (P < .001, P < .001 and P = .039 respectively). Also, total thiol and native thiol (SH) were significantly different between the groups according to OSA severity (mild‐moderate to severe OSA) (P < .001 and P < .001 respectively). Thiol‐disulfide redox parameters were correlated with apnoea‐hypopnoea index (AHI) scores.Conclusion: The present prospective study showed that thiol/disulfide homeostasis was unbalanced in OSA patients. Especially, in OSA patients have low level of thiol/disulfide redox parameters when compared to healthy subjects. Evaluating thiol‐disulfide homeostasis in OSA may be a contributing aspect to assessment and monitoring of the patient.